MedTrace Logo

Safety and Efficacy Study of VIS649 for IgA Nephropathy

NCT04287985 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 155

Last updated 2026-04-24

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the efficacy and safety of VIS649 in participants with immunoglobulin A (IgA) Nephropathy (IgAN)

Conditions

  • Immunoglobulin A Nephropathy
  • Glomerular Disease
  • IgAN

Interventions

DRUG

Dose-Placebo

Unit Dose Strength - 0.9%.

DRUG

Low Dose-VIS649

Dose Level = Low

DRUG

Medium Dose-VIS649

Dose Level = Medium

DRUG

High Dose-VIS649

Dose Level = High

Sponsors & Collaborators

  • Otsuka Pharmaceutical Development & Commercialization, Inc.

    lead INDUSTRY

Principal Investigators

  • Asher Schachter, M.D. · Visterra, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-20
Primary Completion
2023-05-19
Completion
2023-06-18
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Canada
  • Hong Kong
  • India
  • Japan
  • Malaysia
  • Philippines
  • Singapore
  • South Korea
  • Spain
  • Sri Lanka
  • Taiwan
  • Thailand
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04287985 on ClinicalTrials.gov